NGL Fine-Chem Limited (NGLFINE.NS)
INR 1050.1
(-0.78%)
INR 1050.1
(-0.78%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 433.03 Million INR | 60.42% |
| 2022 | 269.93 Million INR | -51.8% |
| 2021 | 560.07 Million INR | 47.97% |
| 2020 | 378.5 Million INR | 35.68% |
| 2019 | 278.96 Million INR | 49.9% |
| 2018 | 186.1 Million INR | 10.71% |
| 2017 | 168.1 Million INR | 42.32% |
| 2016 | 118.11 Million INR | 17.86% |
| 2015 | 100.21 Million INR | -17.32% |
| 2014 | 121.2 Million INR | 42.67% |
| 2013 | 84.95 Million INR | -13.99% |
| 2012 | 98.76 Million INR | 70.9% |
| 2011 | 57.79 Million INR | 20.67% |
| 2010 | 47.89 Million INR | 15.76% |
| 2009 | 41.37 Million INR | 9.13% |
| 2008 | 37.91 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 433.03 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 433.03 Million INR | 60.42% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 388.39 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 269.93 Million INR | 0.0% |
| 2022 FY | 269.93 Million INR | -51.8% |
| 2022 Q2 | 422.4 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 560.07 Million INR | 0.0% |
| 2021 Q2 | 547.52 Million INR | 0.0% |
| 2021 FY | 560.07 Million INR | 47.97% |
| 2020 Q2 | 290.64 Million INR | 0.0% |
| 2020 FY | 378.5 Million INR | 35.68% |
| 2020 Q4 | 378.5 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q2 | 254.49 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 278.96 Million INR | 49.9% |
| 2019 Q4 | 278.96 Million INR | 0.0% |
| 2018 FY | 186.1 Million INR | 10.71% |
| 2018 Q4 | 186.1 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 189.67 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q4 | 168.1 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 168.1 Million INR | 42.32% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 130 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 118.11 Million INR | 17.86% |
| 2016 Q4 | 118.11 Million INR | 0.0% |
| 2016 Q2 | 128.72 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q2 | 127.62 Million INR | 0.0% |
| 2015 FY | 100.21 Million INR | -17.32% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 100.21 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 FY | 121.2 Million INR | 42.67% |
| 2014 Q4 | 121.2 Million INR | 0.0% |
| 2014 Q2 | 102.72 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 84.95 Million INR | -13.99% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 113.43 Million INR | 0.0% |
| 2013 Q4 | 84.95 Million INR | 0.0% |
| 2012 Q4 | 98.76 Million INR | 0.0% |
| 2012 FY | 98.76 Million INR | 70.9% |
| 2011 Q4 | 57.79 Million INR | 0.0% |
| 2011 FY | 57.79 Million INR | 20.67% |
| 2010 FY | 47.89 Million INR | 15.76% |
| 2009 FY | 41.37 Million INR | 9.13% |
| 2008 Q4 | 37.91 Million INR | 0.0% |
| 2008 FY | 37.91 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Abbott India Limited | 6.19 Billion INR | 93.011% |
| Cipla Limited | 52.37 Billion INR | 99.173% |
| Gland Pharma Limited | 16.55 Billion INR | 97.384% |
| GlaxoSmithKline Pharmaceuticals Limited | 5.33 Billion INR | 91.889% |
| Kopran Limited | 1.38 Billion INR | 68.731% |
| Marksans Pharma Limited | 6.17 Billion INR | 92.992% |
| Pfizer Limited | 4.33 Billion INR | 90.015% |
| Sanofi India Limited | 6.63 Billion INR | 93.476% |
| SMS Pharmaceuticals Limited | 2.33 Billion INR | 81.47% |
| TTK Healthcare Limited | 969.89 Million INR | 55.353% |